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Background: Subarachnoid hemorrhage (SAH) is a devastating cause of stroke, occurring in relatively young
people. It has been suggested that some immune-mediated diseases may be associated with an increased risk of
SAH.
Methods: We analysed a database of linked statistical records of hospital admissions and death certificates for the
whole of England (1999–2011). Rate ratios for SAH were determined, comparing immune-mediated disease cohorts
with comparison cohorts.
Results: There were significantly elevated risks of SAH after hospital admission for the following individual
immune-mediated diseases: Addison’s disease, ankylosing spondylitis, autoimmune haemolytic anaemia, Crohn’s
disease, diabetes mellitus, idiopathic thrombocytopenia purpura, myxoedema, pernicious anaemia, primary biliary
cirrhosis, psoriasis, rheumatoid arthritis, scleroderma, Sjogren’s syndrome, SLE and thyrotoxicosis. Elevated risks that
were greater than 2-fold were found for Addison’s disease (rate ratio (RR) = 2.01, 95% confidence interval 1.3-2.97),
idiopathic thrombocytopenia purpura (RR = 2.42, 1.86-3.11), primary biliary cirrhosis (RR = 2.21, 1.43-3.16) and SLE
(RR = 3.76, 3.08-4.55).
Conclusions: Our findings strongly support the suggestion that patients with some immune-mediated diseases
have an increased risk of SAH. Further studies of the mechanisms behind this association are warranted.Background
Subarachnoid haemorrhage (SAH) accounts for approxi-
mately 5% of all strokes [1]. Because it occurs at a rela-
tively young age and has a high case fatality, the loss of
productive life years in the general population from SAH
is as large as that from other stroke types [1]. The mean
age at time of SAH is around 50 years, and the incidence
is around 1 per 10,000 people per year, with particularly
high rates in Japan and Finland, and higher rates in
women than in men [2]. Ruptured aneurysms are the
pathological cause in 85% of patients, whereas 10% fit into
the pattern of non-aneurysmal perimesencephalic haemor-
rhage [1]. The remaining 5% have various rare causes [1].* Correspondence: michael.goldacre@dph.ox.ac.uk
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article, unless otherwise stated.Established personal risk factors for SAH include
smoking, hypertension and excessive alcohol intake [2].
Non-modifiable risk factors include a familial prepon-
derance of SAH, female gender and certain heritable
connective tissue disorders, such as polycystic kidney
disease and Ehlers-Danlos syndrome [2]. In the literature,
there have been case reports and case series of patients
with immune mediated diseases such as systemic lupus er-
ythematosus (SLE) [3] and Sjogren’s syndrome [4] having
SAH, suggesting that there may be a general association
between immune-mediated diseases and SAH. In support
of this, a recent Swedish study of ischemic and haemor-
rhagic strokes (but not specifically SAH) in patients
hospitalised for a variety of immune-mediated diseases
found elevated risks for haemorrhagic stroke in 15
immune-mediated diseases [5].
To investigate this further for SAH, we undertook a
record linkage study to determine the risk of SAH inentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Number of people in the study with each




England, 1999 – 2011
N % of females
Addison’s disease (E27) 11 839 59
Ankylosing spondylitis (M45) 29 136 30
Autoimmune haemolytic anaemia (D59.1) 9 241 54
Chronic active hepatitis (K73.2) 4 439 70
Coeliac disease (K90) 70 715 67
Crohn’s disease (K50) 125 240 56
Dermatomyositis (M33.0-M33.1) 2 768 67
Diabetes mellitus (E10) 426 471 46
Goodpasture’s syndrome (M31) 1 058 49
Hashimoto’s thyroiditis (E06.3) 8 630 90
Idiopathic thrombocytopenia purpura (D69) 31 043 55
Multiple sclerosis (G35) 82 256 69
Myasthenia gravis (G70) 11 279 49
Myxoedema (E03.8–E03.9) 938 696 81
Pemphigoid (L12) 13 642 56
Pemphigus (L10) 2 348 56
Pernicious anaemia (D51.0) 67 890 68
Polyarteritis nodosa (M30.0) 2 249 44
Polymyositis (M33.2) 3 860 62
Primary biliary cirrhosis (K74) 11 146 84
Psoriasis (L40) 119 454 48
Rheumatoid arthritis (M05–M06) 331 393 71
Scleroderma (M34) 11 494 82
Sjogren’s syndrome (M35.0) 17 741 89
Systemic lupus erythematosus (M32) 25 576 86
Thyrotoxicosis (E05) 132 826 79
Ulcerative colitis (K51) 180 397 49
Ramagopalan et al. BMC Neurology 2013, 13:176 Page 2 of 6
http://www.biomedcentral.com/1471-2377/13/176individuals with selected immune-mediated diseases using




We used the complete dataset of English national Hospital
Episode Statistics (HES) from January 1999 to December
2011, inclusive, covering the population of England of
about 50 million people. The HES data were provided by
the English national Health and Social Care Information
Centre (IC). Data from death registrations, covering the
same population and time period, were provided by the
Office for National Statistics (ONS). The dataset used in
this study, in which successive records for each individual
were linked together using personal identifiers irreversibly
encrypted by the IC and ONS, was constructed by the
Oxford record linkage group (file version fce_14yr_v01_
admiyear). Approval for the construction and analysis of
the linked dataset was given by the Central and South
Bristol Research Ethics Committee (ref 04/Q2006/176).
The basic methods were the same for the analysis of
each disease and are described for SLE and SAH. A co-
hort of people with a record of hospital day case care or
inpatient admission for SLE was constructed for those
with a principal diagnosis of SLE, as a reason for hospital
care, by identifying the first episode of day case care, or in-
patient admission, for the condition in an NHS hospital
during the study period. The International Classification
of Disease (ICD) codes used for each immune-mediated
disease are given in Table 1. The ICD codes used for SAH
were 430 in the ninth revision of the ICD (the ninth revi-
sion was used for mortality data in 1999 and 2000) and
I60 in the tenth revision (used for all the hospital data
from 1999 and for mortality data from 2001). A reference
cohort was constructed by identifying the first admission
for each individual with various other, mainly minor med-
ical and surgical conditions and injuries (listed in Table
footnotes). This is based on a ‘control’ group of conditions
that has been used in other similar studies of associations
between diseases [6,7]. In the design of the reference co-
hort using hospital controls, standard epidemiological
practice was followed in selecting a diverse range of condi-
tions, rather than relying on a narrow range (in case the
latter are themselves atypical in their risk of subsequent
disease). As a check, we have studied the risk of SAH in
the control conditions within the reference cohort to en-
sure that the reference cohort does not include control
conditions that have atypically high or low SAH rates.
People were included in the SLE or reference cohort if
they did not have an admission for SAH either before or
at the same time as the admission for SLE or the refer-
ence condition. We then searched the database for any
subsequent NHS hospital care for, or death from, SAHin these cohorts. We considered that rates of SAH in
the reference cohort would approximate those in the
general population of England while allowing for migra-
tion in and out of it (data on migration of individuals
were not available).
Statistical methods
We calculated rates of SAH based on person-days. We
took “date of entry” into each cohort as the date of first
admission for SLE, or reference condition, and “date of
exit” as the date of first record of SAH, death, or the end
of data collection (31st December 2011), whichever was
the earliest. We first calculated rates for SAH, stratified
and then standardised by age (in five-year age groups),
sex, calendar year of first recorded admission, region of
residence, and quintile of patients’ Index of Deprivation
Table 2 Rate ratios1 and 95% confidence intervals (CIs)
for subarachnoid haemorrhage in people with selected




Observed Rate ratio (95% CI) P value
Addison’s disease 25 2.01 (1.3-2.97) 0.001*
Ankylosing spondylitis 46 1.64 (1.2-2.19) 0.001*
Autoimmune haemolytic
anaemia
16 1.99 (1.14-3.23) 0.009
Chronic active hepatitis 1 0.18 (0-0.99) 0.08
Coeliac disease 72 1.04 (0.82-1.32) 0.76
Crohn’s disease 159 1.29 (1.1-1.51) 0.001*
Dermatomyositis 3 1.27 (0.26-3.7) 0.93
Diabetes mellitus 534 1.21 (1.11-1.33) <0.001*
Goodpasture’s syndrome 2 2.31 (0.28-8.34) 0.50
Hashimoto’s thyroiditis 10 0.97 (0.46-1.78) 0.96
Idiopathic thrombocytopenia
purpura
62 2.42 (1.86-3.11) <0.001*
Multiple sclerosis 115 1.09 (0.9-1.31) 0.41
Myasthenia gravis 12 0.93 (0.48-1.62) 0.91
Myxoedema 1283 1.15 (1.09-1.22) <0.001*
Pemphigoid 16 1.29 (0.74-2.1) 0.38
Pemphigus 3 1.35 (0.28-3.94) 0.85
Pernicious anaemia 96 1.3 (1.05-1.59) 0.013
Polyarteritis nodosa 4 1.79 (0.49-4.6) 0.40
Polymyositis 8 1.81 (0.78-3.56) 0.15
Primary biliary cirrhosis 30 2.21 (1.49-3.16) <0.001*
Psoriasis 156 1.34 (1.14-1.57) <0.001*
Rheumatoid arthritis 640 1.48 (1.36-1.6) <0.001*
Scleroderma 25 1.84 (1.19-2.72) 0.003
Sjogren’s syndrome 39 1.69 (1.2-2.31) 0.001*
Systematic lupus
erythematosus
108 3.76 (3.08-4.55) <0.001*
Thyrotoxicosis 202 1.38 (1.19-1.58) <0.001*
Ulcerative colitis 198 1.00 (0.87-1.16) 0.99
1Adjusted for sex, age in 5-year bands, time-period in single calendar years,
region of residence, and deprivation score associated with patients’ local
authority area of residence in quintiles. The rate ratios are calculated as the
ratio of the observed/expected number in the cohort for each immune-mediated
disease to the observed/expected numbers in the reference cohort as
calculated in the analysis undertaken for each of the individual disease
(data not shown).
2Conditions used in reference cohort: appendicectomy, squint, otitis externa,
otitis media, haemorrhoids, deflected nasal septum, nasal polyp, impacted
tooth and other disorders of teeth, inguinal hernia, in-growing toenail and
other diseases of nail, sebaceous cyst, internal derangement of knee, bunion,
dislocations, sprains and strains, superficial injury and contusion.
*Significant P value after full Bonferroni correction = <0.00185.
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used the indirect method of standardisation, and the
combined SLE and reference cohorts as the standard
population. The stratum-specific rates in the combined
SLE and reference cohorts were then applied to the
number of people in each corresponding stratum in the
SLE cohort, and then, separately, to those in the reference
cohort, to obtain an ‘expected’ number of people with
SAH in each stratum within each of the two cohorts. The
stratum-specific observed (O) and expected (E) numbers
were then summed. The rate ratio was then calculated,
taking the observed and expected numbers of SAH in
the SLE cohort relative to those in the reference cohort,
using the formula (OSLE/ESLE) / (OREF/EREF). The rate
ratio, its confidence interval, and χ2 statistics for its sig-
nificance were calculated using standard statistical
methods [9]. We have given exact p values so that
readers can judge what level of statistical significance
each finding has. A full Bonferroni correction for testing
multiple comparisons across twenty seven diseases
would need an exact p value of 0.00185 to be classed as
significant (i.e. p = 0.05/27).
Results
Table 1 shows the number of people in the study who
were admitted to hospital with each of the selected
immune-mediated diseases; it also shows the percentage
of these who were female. The number of people in the
reference cohort was over 7.6 million (48% female).
There were significantly elevated risks of SAH after
hospital admission for the following individual immune-
mediated diseases: Addison’s disease, ankylosing spondyl-
itis, autoimmune haemolytic anaemia, Crohn’s disease,
diabetes mellitus, idiopathic thrombocytopenia purpura,
myxoedema, pernicious anaemia, primary biliary cirrhosis,
psoriasis, rheumatoid arthritis, scleroderma, Sjogren’s
syndrome, SLE and thyrotoxicosis (Table 2).
Levels of risk that were two-fold or higher were found
for Addison’s disease (rate ratio (RR) = 2.01, 95% confi-
dence interval 1.3-2.97), idiopathic thrombocytopenia
purpura (RR = 2.42, 1.86-3.11), primary biliary cirrhosis
(RR = 2.21, 1.43-3.16) and SLE (RR = 3.76, 3.08-4.55).
We studied the occurrence of a first admission for
SAH within a year of the first admission for each
immune-related disease to help establish whether any
elevated risk of SAH was confined to the short-term
(and therefore possibly related to the event of admission
with the immune-mediated disease) or was more pro-
longed, although this analysis reduced statistical power.
Considering SAH that occurred within a year following
the first recorded admission for immune-mediated
disease, there were significantly elevated risks for
Addison’s disease, ankylosing spondylitis, coeliac dis-
ease, diabetes mellitus, idiopathic thrombocytopeniapurpura, myxoedema, pernicious anaemia, primary biliary
cirrhosis, rheumatoid arthritis, systemic lupus erythemato-
sus and thyrotoxicosis (Table 3).
Table 3 Rate ratios and 95% confidence intervals (CIs) for
subarachnoid haemorrhage occurring within a year after
admission for immune-mediated disease
Immune mediated
disease
Observed Rate ratio (95% CI) P value
Addison’s disease 7 2.77 (1.11-5.73) 0.01
Ankylosing spondylitis 12 1.99 (1.02-3.49) 0.03
Autoimmune haemolytic
anaemia
5 2.33 (0.75-5.44) 0.11
Chronic active hepatitis 0 0 (0-3.75) 0.63
Coeliac disease 23 1.62 (1.03-2.45) 0.03
Crohn’s disease 26 1.16 (0.75-1.71) 0.52
Dermatomyositis 1 1.75 (0.04-9.77) 0.93
Diabetes mellitus 144 1.68 (1.40-2.00) <0.001*
Goodpasture’s syndrome 0 0 (0-16.34) 0.56
Hashimoto’s thyroiditis 2 0.95 (0.11-3.42) 0.79
Idiopathic thrombocytopenia
purpura
22 3.72 (2.32-5.66) <0.001*
Multiple sclerosis 28 1.47 (0.97-2.14) 0.06
Myasthenia gravis 4 1.44 (0.39-3.71) 0.66
Myxoedema 460 1.54 (1.38-1.72) <0.001*
Pemphigoid 7 1.91 (0.77-3.94) 0.14
Pemphigus 1 1.75 (0.04-9.77) 0.92
Pernicious anaemia 30 1.5 (1.01-2.15) 0.04
Polyarteritis nodosa 2 4.11 (0.5-14.88) 0.15
Polymyositis 2 2.12 (0.26-7.67) 0.57
Primary biliary cirrhosis 11 3.32 (1.65-5.96) <0.001*
Psoriasis 34 1.31 (0.9-1.84) 0.15
Rheumatoid arthritis 157 1.63 (1.37-1.93) <0.001*
Scleroderma 6 1.9 (0.69-4.14) 0.19
Sjogren’s syndrome 5 0.89 (0.29-2.08) 0.96
Systematic lupus
erythematosus
28 4.78 (3.16-6.95) <0.001*
Thyrotoxicosis 49 1.38 (1.02-1.84) 0.03
Ulcerative colitis 31 0.87 (0.59-1.24) 0.49
*Significant P value after full Bonferroni correction = <0.00185.
Table 4 Rate ratios and 95% confidence intervals (CIs) for
subarachnoid haemorrhage occurring at least a year after
admission for immune-mediated disease
Immune mediated
disease
Observed Rate ratio (95% CI) P value
Addison’s disease 18 1.82 (1.08-2.88) 0.02
Ankylosing spondylitis 34 1.55 (1.07-2.16) 0.01
Autoimmune haemolytic
anaemia
11 1.87 (0.93-3.34) 0.06
Chronic active hepatitis 1 0.21 (0.01-1.2) 0.14
Coeliac disease 49 0.89 (0.66-1.18) 0.48
Crohn’s disease 133 1.32 (1.11-1.57) 0.002
Dermatomyositis 2 1.11 (0.13-4.02) 0.83
Diabetes mellitus 390 1.10 (0.99-1.22) 0.067
Goodpasture’s syndrome 2 3.12 (0.38-11.27) 0.28
Hashimoto’s thyroiditis 8 0.97 (0.42-1.91) 0.93
Idiopathic thrombocytopenia
purpura
40 2.04 (1.45-2.78) <0.001*
Multiple sclerosis 87 1 (0.8-1.24) 0.97
Myasthenia gravis 8 0.79 (0.34-1.55) 0.61
Myxoedema 823 1.02 (0.95-1.1) 0.53
Pemphigoid 9 1.03 (0.47-1.96) 0.94
Pemphigus 2 1.21 (0.15-4.37) 0.91
Pernicious anaemia 66 1.22 (0.95-1.56) 0.12
Polyarteritis nodosa 2 1.15 (0.14-4.15) 0.85
Polymyositis 6 1.72 (0.63-3.75) 0.28
Primary biliary cirrhosis 19 1.86 (1.12-2.9) 0.01
Psoriasis 122 1.35 (1.12-1.62) 0.001*
Rheumatoid arthritis 483 1.44 (1.31-1.58) <0.001*
Scleroderma 19 1.83 (1.1-2.85) 0.012
Sjogren’s syndrome 34 1.94 (1.35-2.72) <0.001*
Systematic lupus
erythematosus
80 3.5 (2.77-4.36) <0.001*
Thyrotoxicosis 153 1.38 (1.16-1.62) <0.001*
Ulcerative colitis 167 1.03 (0.88-1.2) 0.71
*Significant P value after full Bonferroni correction = <0.00185.
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mission for immune-mediated disease, associations were
similar as to those observed for the overall analysis
(Table 2), except that autoimmune haemolytic anaemia,
diabetes mellitus, myxoedema and pernicious anaemia
lost significance (Table 4).
Discussion and conclusion
Previous reports, combined with the results we present
here, suggest that there may be an association between
some immune-mediated diseases and the risk of subse-
quent SAH. Of note, both our study and the Swedish
study of haemorrhagic stroke [5] found increased risks
for ankylosing spondylitis, autoimmune haemolyticanaemia, Crohn’s disease, hyperthyroid conditions, idio-
pathic thrombocytopenia purpura, pernicious anaemia,
psoriasis, rheumatoid arthritis and SLE. However, the
Swedish study did not investigate the SAH subtype of
haemorrhage, and indeed the mechanisms linking
immune-mediated disease to SAH and other haemorrhage
types may differ. Even if the fairly low levels of significant
elevation of risk found in our study, such as those associ-
ated with myxoedema (at 1.15), are considered unimportant
clinically, the high levels of risks associated with some dis-
eases, for example SLE (at 3.76), are striking. This risk does
not appear to be confined to recent hospital admission as
the elevated risk for SAH remained for more than a year
after being admitted for SLE.
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rysms or the process by which they form, grow, and
rupture. The most common histological finding follow-
ing an aneurysm is a decrease in the tunica media of
the involved vessel causing defects of the normal arter-
ial structure. These defects, combined with haemo-
dynamic factors, lead to aneurysmal outpouchings at
arterial branch points in the subarachnoid space at the
base of the brain [10]. Spontaneous SAH is typically
due to arterial bleeding and has been linked to hyper-
tension, smoking and alcohol [11]. More rarely SAH is
associated with vasculitis. We tested a wide variety of
immune-mediated diseases with differing aetiologies in
this exploratory study. The elevated risks may be a reflec-
tion of vasculitis and/or immune or inflammatory influ-
ences upon circulation. Most of the systemic autoimmune
disorders linked to SAH in this study have been associated
with vasculitis. These data therefore raise the possibility
that the SAH is sometimes a manifestation of an associ-
ated focal vasculitis of the intra-cranial arteries. Without
confirmation from pathology, this remains a hypothesis.
Another more intriguing hypothesis is that berry aneu-
rysms, or a proportion of them, are autoimmune and due
to an inflammatory disease of blood vessels. This is par-
tially supported by finding inflammatory infiltrates in the
walls of cerebral aneurysms [12]. Only a few studies have
investigated the possibility of some immunosuppressive
medications commonly used in the treatment of immune-
mediated diseases potentially contributing to an increased
SAH risk. The use of non-steroidal anti-inflammatory
drugs (NSAIDs) does not appear to be associated with an
increased SAH risk [13]. More recently in a Taiwanese
study, the use of a relatively high mean daily dose of
steroid has however been proposed as an independent
risk factor of increased SAH risk in SLE patients, but
this needs to be confirmed or refuted in further work
and in other immune-mediated diseases [14]. Further,
the increased risks of SAH may have different causes in
each disease. For example, type 1 diabetes (T1D) has
recently been associated with a significantly increased
risk of specifically non-aneurysmal SAH [15]. This is
thought to be due to microvascular rather than macrovas-
cular damage, which is known to occur in T1D through
non-immune mediated mechanisms. The mechanism be-
hind the association between SAH and diabetes mellitus
may therefore, at least in part, differ from that of another
immune-mediated disease.
A key strength of the dataset is its size with large
numbers of fairly uncommon diseases. The risk of SAH
was studied within a single population, using the same
methodology, which means that direct comparisons of
risk between different immune-mediated diseases can be
made. The dataset has limitations. The data is based on
prevalent cases of immune disease – the first recordedhospital admission or episode of day case care for each
person with each condition – rather than being a cohort
with follow-up from the date of first diagnosis. The data-
set is limited to people who were admitted to hospital,
or who received day case specialist care. This would not
capture all people with each immune-mediated disease,
although it should identify the great majority with subse-
quent diagnosed SAH. We lack treatment and disability
data for the immune-mediated diseases; and we lack
data on potential confounding factors such as detailed
socioeconomic characteristics, ethnicity, smoking, alcohol
intake and blood pressure. The effect of making multiple
comparisons needs to be considered. It is possible that
some of the associations that are significant at levels close
to p < 0.05 may result from making multiple comparisons
and the play of chance. This may particularly be so where
there is no prior hypothesis to support the finding. On the
other hand, even in a study with the number of compari-
sons that we have made, findings where the significance
level is <0.001 or less, are unlikely to be attributable to
chance alone. We studied 27 different immune-mediated
diseases. At a significance level of p = 0.05, by chance
alone one might expect one or two significant results.
We have reported significant results for 15 of the 27:
these associations with SAH are not the play of chance
but a rather general characteristic of immune-mediated
diseases.
Our findings and their interpretation should be regarded
as speculative rather than definitive. The results represent
what can be done using very large, linked, routinely
collected administrative datasets; but such datasets
lack detail. Alternative designs like epidemiological
field studies - e.g. interviewing patients with SAH and
controls about uncommon prior immune-mediated
diseases, or following up cohorts of people with and
without (say) SLE to identify later risk of SAH - would
be substantial undertakings. Nonetheless, further work
is needed, in different study designs, to confirm or refute
the findings. Further studies should look at individual
immune-mediated diseases in greater depth to aid un-
derstanding of mechanisms behind any association. This
may be particularly warranted in people with diseases at
relatively high risk of SAH, such as SLE.
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